

# Human AGS NOD1 KO (Clone 41A8) Cell Line

**Catalogue number:** 153733

**Sub-type:** Continuous

**Images:**

## Contributor

**Inventor:** Richard Ferrero

**Institute:** Hudson Institute of Medical Research

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Human AGS NOD1 KO (Clone 41A8) Cell Line

**Alternate name:** Human nucleotide-binding oligomerization domain-containing protein 1, NOD1.

**Class:**

**Conjugate:**

**Description:** NOD1 responds to *Helicobacter pylori* infection in a Type IV secretion system-dependent manner. *H. pylori* causes chronic inflammation, a key precursor to gastric adenocarcinoma. AGS cells deficient in NOD1 (as generated by CRISPR) can be used to model gastric adenocarcinoma in the context of various pathogens. NOD1 regulates host epithelial cell responses. Upregulates antimicrobial peptides of the beta-defensin (hBD) family secreted by epithelial cells.

**Purpose:**

**Parental cell:** AGS

**Organism:** Human

**Tissue:** Gastric

**Model:** Knock-Out

**Gender:**

**Isotype:**

**Reactivity:**

**Selectivity:**

**Host:**

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:** Epithelial-like morphology

**Production details:** CRISPR/Cas9 gene editing was used to generate NOD1 knock out clones. AGS cells were transfected with vectors expressing Cas9 nickase • nuclease

and pairs of guide RNAs (gRNAs) specific for the NOD1 gene. Clone 41A8 was confirmed as having a 71 base pair deletion within the coding regions of the caspase activation and recruitment domain (CARD) of NOD1. Recommended Freezing Composition: 90% (v/v) FCS - 10% (v/v) DMSO

**Formulation:**

**Recommended controls:** NOD1 Ligand: C12-iE-DAP (10 ng/ml)

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:** Recommended Freezing Composition: 90% (v/v) FCS - 10% (v/v) DMSO CRISPR edited Human AGS cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CR...

## Target details

**Target:** Human nucleotide-binding oligomerization domain-containing protein 1

**Target alternate names:**

**Target background:**

**Molecular weight:**

**Ic50:**

## Applications

**Application:**

**Application notes:** Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: [https://www.cancertools.org/tool-faqs#hs\\_cos\\_wrapper\\_widget\\_1649861453796](https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796) This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

## Handling

**Format:** Frozen

**Concentration:**

**Passage number:**

**Growth medium:** RPMI with: 10% foetal calf serum; 1% penicillin-streptomycin; and 1% L-glutamine. Subculture cells every 2-3 days in ratios of 1:2-1:4 in T25 or T75 flasks.

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:**

**Storage conditions:** Liquid Nitrogen

**Shipping conditions:** Dry ice

## Related tools

**Related tools:** Human AGS NOD1 KO (Clone 41H8) Cell Line ; Human AGS NOD1 KD (AGS cl.1) Cell Line

## References

**References:**

CancerTools.org